



Louisiana

Dermatologic Applications of Photodynamic Therapy

Policy # 00098

Original Effective Date: 06/05/2002

Current Effective Date: 06/14/2021

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Light Therapy for Psoriasis is addressed separately in medical policy 00131.

Note: Oncologic Applications of Photodynamic Therapy, Including Barrett's Esophagus is addressed separately in medical policy 00234.

Note: Photodynamic Therapy for Choroidal Neovascularization is addressed separately in medical policy 00097.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider photodynamic therapy (PDT) to be **eligible for coverage.****

Patient Selection Criteria

Coverage eligibility will be considered for any of the following conditions:

- Actinic keratosis; or
- Low-risk (e.g. superficial and nodular) basal cell skin cancer only when surgery and radiation are contraindicated; or
- Cutaneous squamous cell carcinoma in situ (Bowen disease) only when surgery and radiation are contraindicated.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Dermatologic Applications of Photodynamic Therapy

Policy # 00098

Original Effective Date: 06/05/2002

Current Effective Date: 06/14/2021

When Services Are Not Covered

The use of photodynamic therapy (PDT) as a technique of skin rejuvenation, hair removal, or other cosmetic indications is **not covered**. **

When Services Are Considered Investigational

Note: Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers photodynamic therapy (PDT) for other dermatologic applications, including, but not limited to the following to be **investigational**.*

- Acne vulgaris
- High-risk basal cell carcinomas
- Hidradenitis suppurativa
- Mycoses

Based on the review of available data, the Company considers the use of photodynamic therapy (PDT) when patient selection criteria are not met to be **investigational**.*

Policy Guidelines

Surgery and radiation are the preferred treatments for low-risk basal cell cancer and Bowen disease. If photodynamic therapy is selected for these indications because of contraindications to surgery or radiation, patients and physicians need to be aware that it may have a lower cure rate than surgery or radiation.

Photodynamic therapy typically involves 2 office visits: one to apply the topical aminolevulinic acid and a second visit to expose the patient to blue light. The second physician office visit, performed solely to administer blue light, should not warrant a separate Evaluation and Management CPT code. Photodynamic protocols typically involve 2 treatments spaced a week apart; more than 1 treatment series may be required.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Dermatologic Applications of Photodynamic Therapy

Policy # 00098

Original Effective Date: 06/05/2002

Current Effective Date: 06/14/2021

Based on characteristics of patients enrolled in randomized controlled trials, 4 or more lesions per site (face, scalp, or upper extremities) is an appropriate threshold for use of photodynamic therapy for patients with nonhyperkeratotic actinic keratosis.

Background/Overview

Photodynamic Therapy

PDT refers to light activation of a photosensitizer to generate highly reactive intermediaries, which ultimately cause tissue injury and necrosis. Two common photosensitizing agents are 5-aminolevulinic acid (5-ALA) and its methyl ester, methyl aminolevulinate. When applied topically, these agents pass readily through abnormal keratin overlying the lesion and accumulate preferentially in dysplastic cells. The agents 5-ALA and methyl aminolevulinate are metabolized by underlying cells to photosensitizing concentrations of porphyrins. Subsequent exposure to photo activation (maximum absorption at 404 to 420 nm and 635 nm) generates reactive oxygen species that are cytotoxic, ultimately destroying the lesion. PDT can cause erythema, burning, and pain. Healing occurs within 10 to 14 days, with generally acceptable cosmetic results. PDT with topical ALA has been investigated primarily as a treatment of actinic keratoses (AKs).

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

In 1999, Levulan[®]‡ Kerastick[™]‡, a topical preparation of ALA, in conjunction with illumination with the BLU-U[™]‡ Blue Light Photodynamic Therapy Illuminator, was approved by the U.S. FDA for the treatment of nonhyperkeratotic AKs of the face and scalp. In 2018, the indication was expanded to include nonhyperkeratotic AKs of the upper extremities. The product is applied in the physician's office. FDA product code: MVF.

In 2016, the FDA approved Ameluz[®]‡ (aminolevulinic acid hydrochloride) gel, 10% (BF-200 ALA; Biofrontera AG) in combination with PDT using BF-RhodoLED lamp, to be used for the lesion-directed and field-directed treatment of AKs of mild-to-moderate severity on the face and scalp. The treatment is to be administered by a healthcare provider.

A 5-ALA patch technology is available outside of the US through an agreement between Intendis (now Bayer HealthCare) and Photonamic. The 5-ALA patch is not approved by the FDA.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Dermatologic Applications of Photodynamic Therapy

Policy # 00098

Original Effective Date: 06/05/2002

Current Effective Date: 06/14/2021

Another variant of PDT for skin lesions is Metvixia[®]‡ used with the Aktilite CL128 lamp, each of which received the FDA approval in 2004. Metvixia (Galderma; Photocure) consists of the topical application of methyl aminolevulinate (in contrast to ALA used in the Kerastick procedure), followed by exposure with the Aktilite CL128 lamp, a red light source (in contrast to the blue light source in the Kerastick procedure). Broadband light sources (containing the appropriate wavelengths), intense pulsed light (FDA product code: ONF), pulsed dye lasers, and potassium-titanyl-phosphate lasers have also been used. Metvixia is indicated for the treatment of nonhyperkeratotic AKs of the face and scalp in immunocompetent patients when used with lesion preparation (débridement using a sharp dermal curette) in the physician's office when other therapies are unacceptable or considered medically less appropriate. FDA product codes: GEX and LNK.

Rationale/Source

Photodynamic therapy (PDT) refers to light activation of a photosensitizer to generate highly reactive intermediaries, which ultimately cause tissue injury and necrosis. Photosensitizing agents are being proposed for use with dermatologic conditions such as AKs and nonmelanoma skin cancers.

For individuals who have nonhyperkeratotic AKs on the face or scalp who receive PDT, the evidence includes randomized controlled trials (RCTs). The relevant outcomes are symptoms, change in disease status, quality of life (QOL), and treatment-related morbidity. Evidence from multiple RCTs has found that PDT improves the net health outcome in patients with nonhyperkeratotic AKs on the face or scalp compared with placebo or other active interventions. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have nonhyperkeratotic AKs on the upper extremities who receive PDT, the evidence includes RCTs. The relevant outcomes are symptoms, change in disease status, QOL, and treatment-related morbidity. In two placebo-controlled RCTs, significantly more patients had a complete clearance of AKs with ALA/PDT with blue light compared to placebo at 12 weeks, and a third found a significantly greater reduction in mean lesion count at 4 weeks. Two small RCTs compared ALA/PDT using red light to imiquimod or 5-fluorouracil and found similar efficacy between the active treatment groups after six months of follow-up. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Dermatologic Applications of Photodynamic Therapy

Policy # 00098

Original Effective Date: 06/05/2002

Current Effective Date: 06/14/2021

For individuals who have low-risk basal cell carcinoma who receive PDT, the evidence includes RCTs and systematic reviews of RCTs. The relevant outcomes are symptoms, change in disease status, QOL, and treatment-related morbidity. Systematic reviews of RCTs have found that PDT may not be as effective as surgery for superficial and nodular basal cell carcinoma. In the small number of trials available, PDT was more effective than a placebo. The available evidence from RCTs has suggested that PDT has better cosmetic outcomes than surgery. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have squamous cell carcinoma in situ who receive PDT, the evidence includes RCTs. The relevant outcomes are symptoms, change in disease status, QOL, and treatment-related morbidity. RCTs have found that PDT has similar or greater efficacy compared with cryotherapy and 5-fluorouracil. Additionally, adverse events and cosmetic outcomes appear to be better after PDT. Few RCTs have compared PDT with surgery or radiotherapy; as a result, conclusions cannot be drawn about PDT compared with these other standard treatments. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have nonmetastatic invasive squamous cell carcinoma who receive PDT, the evidence includes observational studies and a systematic review of observational studies. The relevant outcomes are overall survival, symptoms, change in disease status, QOL, and treatment-related morbidity. Conclusions cannot be drawn from small, uncontrolled studies. RCTs are needed to determine the safety and efficacy of PDT for this condition. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have acne who receive PDT, the evidence includes RCTs and a systematic review. The relevant outcomes are symptoms, change in disease status, QOL, and treatment-related morbidity. The available RCTs have not consistently found significantly better outcomes with PDT compared with other interventions, and a meta-analysis did not find significantly better results with PDT vs placebo. Several trials have found that PDT is associated with high rates of adverse events leading to the cessation of treatment. Trials tended to have relatively small sample sizes and used a variety of comparison interventions. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have noncancerous dermatologic skin conditions (eg, hidradenitis suppurativa, mycoses, port-wine stain) who receive PDT, the evidence includes case series, systematic reviews

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Dermatologic Applications of Photodynamic Therapy

Policy # 00098

Original Effective Date: 06/05/2002

Current Effective Date: 06/14/2021

of uncontrolled series, and an RCT for port-wine stain. The relevant outcomes are symptoms, change in disease status, QOL, and treatment-related morbidity. RCTs are needed to determine the safety and efficacy of PDT for these conditions. The evidence is insufficient to determine the effects of the technology on health outcomes.

Supplemental Information

Practice Guidelines and Position Statements

American Academy of Dermatology

The American Academy of Dermatology has guidelines addressing use of PDT in basal cell carcinoma and acne:

- Basal cell carcinoma (2018): Use of topical therapies, including PDT, is most appropriate for low-risk basal cell carcinoma when surgery is impractical or declined by the patient. Discussions of the relative effectiveness of topical therapies should be discussed with the patient. The guideline further notes that "Cure rates after surgical excision are 10% to 20% higher than those for topical therapies, including PDT, with excision associated with recurrence rates of less than 5%. Surgical excision may also be less painful and better tolerated."
- Acne (2016): More studies are needed on the use of PDT or other laser/light devices. PDT has the most evidence among laser/light devices for treating acne, but "additional studies are needed to determine the optimal photosensitizer, incubation time, and light source."

Canadian Dermatology Association

In 2015, the Canadian Dermatology Association published the following recommendations on the dermatologic use of PDT:

- Basal cell carcinoma: PDT may be used for superficial basal cell carcinoma when nonsurgical treatment is desired, there are multiple carcinomas, and when the cosmetic outcome is important. PDT is not appropriate for nodular basal cell carcinoma.
- Actinic keratosis: PDT is among the recommended treatment options for actinic keratosis, although the guidance includes the statement that cryosurgery or a surgical procedure are preferred for isolated actinic keratosis and hypertonic lesions.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Dermatologic Applications of Photodynamic Therapy

Policy # 00098

Original Effective Date: 06/05/2002

Current Effective Date: 06/14/2021

National Comprehensive Cancer Network

For treatment of precancers (diffuse actinic keratoses, field cancerization), the NCCN (squamous cell skin cancer, v.2.2020) made the following recommendations: "Accepted treatment modalities include cryotherapy, topical 5-fluorouracil (5-FU) with or without calcipotriol (calcipotriene), topical imiquimod, topical ingenol mebutate, photodynamic therapy (e.g., aminolevulinic acid, porfimer sodium), and curettage and electrodesiccation. For hyperkeratotic actinic keratoses, pretreatment with topical tazarotene, curettage, or topical keratolytics (topical urea, lactic acid, and salicylic acid) prior to above therapies may be considered."

For basal cell skin cancer, the NCCN (v.1.2020) made the following recommendations: "In patients with low-risk, superficial basal cell skin cancer, where surgery and radiation are not feasible, therapies such as topical imiquimod, topical 5-fluorouracil, photodynamic therapy (eg, aminolevulinic acid [ALA], porfimer sodium), or vigorous cryotherapy may be considered, even though the cure rates may be lower than with surgical treatment modalities."

For squamous cell skin cancers, the NCCN (v.2.2020) made the following recommendations: "In patients with SCC [squamous cell carcinoma] in situ (Bowen's disease) alternative, therapies such as topical 5-fluorouracil, topical imiquimod, photodynamic therapy (eg, ALA, porfimer sodium), or vigorous cryotherapy may be considered, even though the cure rates may be lower than with surgical treatment modalities."

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

The Centers for Medicare & Medicaid Services' 2001 coverage policy on the treatment of actinic keratosis noted:

"Various options exist on treating AKs [actinic keratosis]. Clinicians should select an appropriate treatment based on the patient's history, the lesion's characteristics, and the patient's preference for specific treatment.... Less commonly performed treatments for AKs include dermabrasion, excision, chemical peels, laser therapy, and photodynamic therapy..."

Medicare covers the destruction of actinic keratosis without restrictions based on lesion or patient characteristics."

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Dermatologic Applications of Photodynamic Therapy

Policy # 00098

Original Effective Date: 06/05/2002

Current Effective Date: 06/14/2021

Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this review are listed in Table 1.

Table 1. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT02367547 ^a	Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitises: Hexylaminolevulinate and Aminolevulinic Acid Nano Emulsion Versus Methylaminolevulinate	117	Dec 2025
NCT03573401 ^a	A Randomized, Double-Blind, Vehicle-controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz [®])‡ and BF-RhodoLED [®] ‡ in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT)	186	Feb 2026
<i>Unpublished</i>			
NCT03025724 ^a	Photodynamic Therapy for Treatment of Cutaneous Squamous Cell Carcinoma in Situ	40	Jan 2020 (last update Jan 2017)
NCT03511326 ^a	Subject Reported Outcomes on Satisfaction, Safety and Efficacy With Luxerm [®] ‡ in the Field-directed Treatment of Thin or Non-hyperkeratotic and Non-pigmented Actinic Keratosis of the Face or the Scalp	50	Nov 2017 (completed)
NCT01482104	A Randomized Controlled Blinded Multi-centre Study of Photodynamic Therapy With Methyl-aminolevulinate Comparing a Simplified Regime With the Approved Regime in Patients With Clinical Low-risk Superficial and Nodular Basal Cell Carcinoma.	277	Oct 2017 (completed)

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Dermatologic Applications of Photodynamic Therapy

Policy # 00098

Original Effective Date: 06/05/2002

Current Effective Date: 06/14/2021

NCT No.	Trial Name	Planned Enrollment	Completion Date
NCT02685592	Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream (LM PDT)	10	Mar 2018 (completed)

NCT: national clinical trial.

^a Denotes industry-sponsored or cosponsored trial.

References

1. Blue Cross and Blue Shield Association, Medical Policy Reference Manual, “Dermatologic Applications of Photodynamic Therapy” 2.01.44. 01:2021.
2. Patel G, Armstrong AW, Eisen DB. Efficacy of photodynamic therapy vs other interventions in randomized clinical trials for the treatment of actinic keratoses: a systematic review and meta-analysis. *JAMA Dermatol.* Dec 2014;150(12):1281-1288. PMID 25162181
3. Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. *J Am Acad Dermatol.* Feb 2003;48(2):227-232. PMID 12582393
4. Morton C, Campbell S, Gupta G, et al. Intraindividual, right-left comparison of topical methyl aminolaevulinate- photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. *Br J Dermatol.* Nov 2006;155(5):1029-1036. PMID 17034536
5. Hauschild A, Stockfleth E, Popp G, et al. Optimization of photodynamic therapy with a novel self-adhesive 5- aminolaevulinic acid patch: results of two randomized controlled phase III studies. *Br J Dermatol.* May 2009;160(5):1066-1074. PMID 19222455
6. Szeimies RM, Radny P, Sebastian M, et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study. *Br J Dermatol.* Aug 2010;163(2):386-394. PMID 20518784
7. Szeimies RM, Stockfleth E, Popp G, et al. Long-term follow-up of photodynamic therapy with a self-adhesive 5- aminolaevulinic acid patch: 12 months data. *Br J Dermatol.* Feb 1 2010;162(2):410-414. PMID 19804593
8. Serra-Guillen C, Nagore E, Hueso L, et al. A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Dermatologic Applications of Photodynamic Therapy

Policy # 00098

Original Effective Date: 06/05/2002

Current Effective Date: 06/14/2021

- application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes. *J Am Acad Dermatol.* Apr 2012;66(4):e131-137. PMID 22226430
9. Dirschka T, Radny P, Dominicus R, et al. Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo. *Br J Dermatol.* Jan 2012;166(1):137-146. PMID 21910711
 10. Dirschka T, Radny P, Dominicus R, et al. Long-term (6 and 12 months) follow-up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. *Br J Dermatol.* Apr 2013;168(4):825-836. PMID 23252768
 11. Giehl KA, Kriz M, Grahovac M, et al. A controlled trial of photodynamic therapy of actinic keratosis comparing different red light sources. *Eur J Dermatol.* May-Jun 2014;24(3):335-341. PMID 24876164
 12. Rubel DM, Spelman L, Murrell DF, et al. Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial. *Br J Dermatol.* Nov 2014;171(5):1164-1171. PMID 24861492
 13. Neittaanmaki-Perttu N, Karppinen TT, Gronroos M, et al. Daylight photodynamic therapy for actinic keratoses: a randomized double-blinded nonsponsored prospective study comparing 5-aminolaevulinic acid nanoemulsion (BF-200) with methyl-5-aminolaevulinate. *Br J Dermatol.* Nov 2014;171(5):1172-1180. PMID 25109244
 14. Zane C, Facchinetti E, Rossi MT, et al. A randomized clinical trial of photodynamic therapy with methyl aminolaevulinate vs. diclofenac 3% plus hyaluronic acid gel for the treatment of multiple actinic keratoses of the face and scalp. *Br J Dermatol.* May 2014;170(5):1143-1150. PMID 24506666
 15. Reinhold U, Dirschka T, Ostendorf R, et al. A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz((R))) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-RhodoLED((R)) lamp. *Br J Dermatol.* Oct 2016;175(4):696-705. PMID 26921093
 16. Yazdanyar S, Zarchi K, Jemec GBE. Pain during topical photodynamic therapy - comparing methyl aminolevulinate (Metvix((R))) to aminolaevulinic acid (Ameluz((R))); an intra-individual clinical study. *Photodiagnosis Photodyn Ther.* Aug 02 2017. PMID 28780136

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Dermatologic Applications of Photodynamic Therapy

Policy # 00098

Original Effective Date: 06/05/2002

Current Effective Date: 06/14/2021

17. Brian Jiang SI, Kempers S, Rich P et al. A Randomized, Vehicle-Controlled Phase 3 Study of Aminolevulinic Acid Photodynamic Therapy for the Treatment of Actinic Keratoses on the Upper Extremities.. *Dermatol Surg*, 2019 Jan 15;45(7). PMID 30640777
18. Schmieder GJ, Huang EY, Jarratt M. A multicenter, randomized, vehicle-controlled phase 2 study of blue light photodynamic therapy with aminolevulinic acid HCl 20% topical solution for the treatment of actinic keratoses on the upper extremities: the effect of occlusion during the drug incubation period.. *J Drugs Dermatol*, 2013 Feb 5;11(12). PMID 23377520
19. Taub AF, Garretson CB. A randomized, blinded, bilateral intraindividual, vehicle-controlled trial of the use of photodynamic therapy with 5-aminolevulinic acid and blue light for the treatment of actinic keratoses of the upper extremities.. *J Drugs Dermatol*, 2011 Nov 5;10(9). PMID 22052276
20. Sotiriou E, Apalla Z, Maliamani F et al. Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities.. *J Eur Acad Dermatol Venereol*, 2009 May 28;23(9). PMID 19470041
21. Kurwa HA, Yong-Gee SA, Seed PT et al. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses.. *J. Am. Acad. Dermatol.*, 1999 Aug 25;41(3 Pt 1). PMID 10459115
22. Wang H, Xu Y, Shi J, et al. Photodynamic therapy in the treatment of basal cell carcinoma: a systematic review and meta-analysis. *Photodermatol Photoimmunol Photomed.* Jan 2015;31(1):44-53. PMID 25377432
23. Zou Y, Zhao Y, Yu J, et al. Photodynamic therapy versus surgical excision to basal cell carcinoma: meta- analysis. *J Cosmet Dermatol.* Dec 2016;15(4):374-382. PMID 27363535
24. Bath-Hextall FJ, Perkins W, Bong J, et al. Interventions for basal cell carcinoma of the skin. *Cochrane Database Syst Rev.* Jan 24 2007(1):CD003412. PMID 17253489
25. Roozeboom MH, Arits AH, Mosterd K, et al. Three-year follow-up results of photodynamic therapy vs. imiquimod vs. fluorouracil for treatment of superficial basal cell carcinoma: a single-blind, noninferiority, randomized controlled trial. *J Invest Dermatol.* Aug 2016;136(8):1568-1574. PMID 27113429
26. Szeimies RM, Ibbotson S, Murrell DF, et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. *J Eur Acad Dermatol Venereol.* Nov 2008;22(11):1302-1311. PMID 18624836

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Dermatologic Applications of Photodynamic Therapy

Policy # 00098

Original Effective Date: 06/05/2002

Current Effective Date: 06/14/2021

27. Rhodes LE, de Rie M, Enstrom Y, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. *Arch Dermatol.* Jan 2004;140(1):17-23. PMID 14732655
28. Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. *Arch Dermatol.* Sep 2007;143(9):1131-1136. PMID 17875873
29. Bath-Hextall FJ, Matin RN, Wilkinson D, et al. Interventions for cutaneous Bowen's disease. *Cochrane Database Syst Rev.* Jun 24 2013;6(6):CD007281. PMID 23794286
30. Morton C, Horn M, Leman J, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial. *Arch Dermatol.* Jun 2006;142(6):729-735. PMID 16785375
31. Salim A, Leman JA, McColl JH, et al. Randomized comparison of photodynamic therapy with topical 5- fluorouracil in Bowen's disease. *Br J Dermatol.* Mar 2003;148(3):539-543. PMID 12653747
32. Lansbury L, Bath-Hextall F, Perkins W, et al. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. *BMJ.* Nov 04 2013;347:f6153. PMID 24191270
33. Barbaric J, Abbott R, Posadzki P, et al. Light therapies for acne. *Cochrane Database Syst Rev.* Sep 27 2016;9:CD007917. PMID 27670126
34. Nicklas C, Rubio R, Crdenas C et al. Comparison of efficacy of aminolaevulinic acid photodynamic therapy vs. adapalene gel plus oral doxycycline for treatment of moderate acne vulgaris-A simple, blind, randomized, and controlled trial.. *Photodermatol Photoimmunol Photomed.* 2018 Jul 12;35(1). PMID 29993146
35. Xu X, Zheng Y, Zhao Z et al. Efficacy of photodynamic therapy combined with minocycline for treatment of moderate to severe facial acne vulgaris and influence on quality of life.. *Medicine (Baltimore).* 2018 Feb 3;96(51). PMID 29390528
36. Pariser DM, Eichenfield LF, Bukhalo M, et al. Photodynamic therapy with methyl aminolaevulinate 80 mg g(-1) for severe facial acne vulgaris: a randomized vehicle-controlled study. *Br J Dermatol.* Apr 2016;174(4):770-777. PMID 26663215
37. Orringer JS, Sachs DL, Bailey E, et al. Photodynamic therapy for acne vulgaris: a randomized, controlled, split- face clinical trial of topical aminolevulinic acid and pulsed dye laser therapy. *J Cosmet Dermatol.* Mar 2010;9(1):28-34. PMID 20367670

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Dermatologic Applications of Photodynamic Therapy

Policy # 00098

Original Effective Date: 06/05/2002

Current Effective Date: 06/14/2021

38. Wiegell SR, Wulf HC. Photodynamic therapy of acne vulgaris using methyl aminolaevulinate: a blinded, randomized, controlled trial. *Br J Dermatol.* May 2006;154(5):969-976. PMID 16634903
39. Wu Q, Tu P, Zhou G et al. A dose-finding study for hemoporphin in photodynamic therapy for port-wine stain: A multicenter randomized double-blind phase IIb trial.. *Photodermatol Photoimmunol Photomed.* 2018 Mar 14;34(5). PMID 29533491
40. Gold M, Bridges TM, Bradshaw VL, et al. ALA-PDT and blue light therapy for hidradenitis suppurativa. *J Drugs Dermatol.* Jan-Feb 2004;3(1 Suppl):S32-35. PMID 14964759
41. Schweiger ES, Riddle CC, Aires DJ. Treatment of hidradenitis suppurativa by photodynamic therapy with aminolevulinic acid: preliminary results. *J Drugs Dermatol.* Apr 2011;10(4):381-386. PMID 21455548
42. Calzavara-Pinton PG, Venturini M, Capezzer R, et al. Photodynamic therapy of interdigital mycoses of the feet with topical application of 5-aminolevulinic acid. *Photodermatol Photoimmunol Photomed.* Jun 2004;20(3):144- 147. PMID 15144392
43. Mostafa D, Tarakji B. Photodynamic therapy in treatment of oral lichen planus. *J Clin Med Res.* Jun 2015;7(6):393-399. PMID 25883701
44. Yazdani Abyaneh MA, Falto-Aizpurua L, Griffith RD, et al. Photodynamic therapy for actinic cheilitis: a systematic review. *Dermatol Surg.* Feb 2015;41(2):189-198. PMID 25627629
45. Xiao Q, Li Q, Yuan KH, et al. Photodynamic therapy of port-wine stains: long-term efficacy and complication in Chinese patients. *J Dermatol.* Dec 2011;38(12):1146-1152. PMID 22032688
46. Zloty D, Guenther LC, Sapijaszko M, et al. Non-melanoma skin cancer in Canada. Chapter 4: Management of basal cell carcinoma. *J Cutan Med Surg.* May-Jun 2015;19(3):239-248. PMID 25986316
47. Poulin Y, Lynde CW, Barber K, et al. Non-melanoma skin cancer in Canada. Chapter 3: Management of actinic keratoses. *J Cutan Med Surg.* May-Jun 2015;19(3):227-238. PMID 25926621
48. National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in Oncology: Squamous Cell Skin Cancer. Version 1.2020. https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf.
49. National Comprehensive Cancer Network (NCCN). NCCN Practice Guidelines in Oncology: Basal cell skin cancer. Version 1.2020. https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf.
50. Centers for Medicare and Medicaid Services. National Coverage Determination (NCD) for Treatment of Actinic Keratosis (250.4). 2011; <https://www.cms.gov/medicare-coverage->

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Dermatologic Applications of Photodynamic Therapy

Policy # 00098

Original Effective Date: 06/05/2002

Current Effective Date: 06/14/2021

database/details/nccdetails.aspx?NCAId=238&NcaName=Allogeneic+Hematopoietic+Stem+Cell+Transplantation+(HSCT)+for+Myelodysplastic+Syndrome&ExpandComments=y&CommentPeriod=0&NCDId=129&ncdver=1&bc=AiAAAAAIEAAA A%3D%3D&

Policy History

Original Effective Date: 06/05/2002

Current Effective Date: 06/14/2021

05/16/2002 Medical Policy Committee review

06/05/2002 Managed Care Advisory Council approval

05/04/2004 Medical Director review

05/18/2004 Medical Policy Committee review. Format revision. No substance change to policy.

06/28/2004 Managed Care Advisory Council approval

06/07/2005 Medical Director review

06/21/2005 Medical Policy Committee review. Clinical criteria revision. Added coverage eligibility and investigational statement for Metvixia. Added acne, mycoses, and hidradenitis suppurativa as investigational indications for aminolevulinic acid.

07/15/2005 Managed Care Advisory Council approval

06/05/2006 Medical Director review

06/21/2006 Medical Policy Committee approval. Format revisions, FDA/Governmental, No change in policy statement.

11/07/2007 Medical Director review

11/15/2007 Medical Policy Committee approval. Title changed and policy replaced.

12/03/2008 Medical Director review

12/17/2008 Medical Policy Committee approval. No change to coverage eligibility.

12/04/2009 Medical Policy Committee approval

12/16/2009 Medical Policy Implementation Committee approval. No change to coverage eligibility

11/04/2010 Medical Policy Committee approval

11/16/2010 Medical Policy Implementation Committee approval. Removed the restriction of face and scalp from the criteria for treatment of non-hyperkeratotic actinic keratoses.

12/08/2011 Medical Policy Committee review

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Dermatologic Applications of Photodynamic Therapy

Policy # 00098

Original Effective Date: 06/05/2002

Current Effective Date: 06/14/2021

12/21/2011	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
12/06/2012	Medical Policy Committee review
12/19/2012	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/23/2013	Updated coverage eligibility statement when patient selection criteria not met
12/12/2013	Medical Policy Committee review
12/18/2013	Medical Policy Implementation Committee approval. No change to coverage.
12/04/2014	Medical Policy Committee review
12/17/2014	Medical Policy Implementation Committee approval. “for other dermatologic applications, including, but not limited to the following” was added to the investigational statement.
08/03/2015	Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
12/03/2015	Medical Policy Committee review
12/16/2015	Medical Policy Implementation Committee approval. No change to coverage.
12/01/2016	Medical Policy Committee review
12/21/2016	Medical Policy Implementation Committee approval. Changes to language in policy statements: Superficial or nodular changed to Low-risk and non-superficial changed to high-risk.
01/01/2017	Coding update: Removing ICD-9 Diagnosis Codes
12/07/2017	Medical Policy Committee review
12/20/2017	Medical Policy Implementation Committee approval. No change to coverage.
01/01/2018	Coding update
12/06/2018	Medical Policy Committee review
12/19/2018	Medical Policy Implementation Committee approval. Removed the word non hyperkeratotic from coverage statement. Added policy guidelines.
12/05/2019	Medical Policy Committee review
12/11/2019	Medical Policy Implementation Committee approval. Deleted the specification of face and scalp from eligible for coverage requirement in the statement for actinic keratosis.
02/06/2020	Medical Policy Committee review
02/12/2020	Medical Policy Implementation Committee approval. No change to coverage.
05/07/2020	Medical Policy Committee review

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Dermatologic Applications of Photodynamic Therapy

Policy # 00098

Original Effective Date: 06/05/2002

Current Effective Date: 06/14/2021

05/13/2020 Medical Policy Implementation Committee approval. No change to coverage.

05/06/2021 Medical Policy Committee review

05/12/2021 Medical Policy Implementation Committee approval. No change to coverage.

Next Scheduled Review Date: 05/2022

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)‡, copyright 2020 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	96567, 96573, 96574
HCPCS	J7308, J7309, J7345

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Dermatologic Applications of Photodynamic Therapy

Policy # 00098

Original Effective Date: 06/05/2002

Current Effective Date: 06/14/2021

ICD-10 Diagnosis	A00.0, B48.1, B48.8, C44.00-C44.09, C50.011-C50.019, C84.00-C84.09, D04.0-D04.9, D06.0-D06.9, L11.8-L11.9, L57.0, L57.2, L57.4, L66.4, L70.0-L70.9, L72.0, L72.2-L72.9, L73.0, L73.2, L74.52, L74.8, L75.0-L75.1, L75.8, L82.0, L85.8, L87.1, L87.8, L90.3-L90.4, L90.8, L91.8, L92.2, L94.8, L98.5-L98.6, L99, N49.0
------------------	---

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 - 1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
 - 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 - 3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Dermatologic Applications of Photodynamic Therapy

Policy # 00098

Original Effective Date: 06/05/2002

Current Effective Date: 06/14/2021

- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.